Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
(Thomson Reuters ONE) -
Press Release - No. 3/2017
Zealand Pharma discloses amylin as the biological target under their 2014
agreement with Boehringer Ingelheim
* Long-acting amylin analogue data are showing significant anti-obesity
effects in preclinical models
* Data will be presented at the Keystone Symposia on May 12, 2017
* Phase 1 clinical trial expected to start 2017, triggering a milestone
payment to Zealand
Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer
Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue
ZP4982 prevents the development of obesity in preclinical models, suggesting its
potential use in treating obesity and obesity-related comorbidities. Zealand and
Boehringer Ingelheim will jointly present these data at the Keystone Symposia
'Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of
Metabolism' on Friday May 12 in Copenhagen, Denmark.
Worldwide, obesity has more than doubled since 1980. In 2014, more than 1.9
billion adults, 18 years and older, were overweight. Of these, over 600 million
were obese.[i]
Amylin is a pancreatic peptide hormone that, through its satiety signaling
effects, inhibits food intake and holds potential as a novel anti-obesity
therapy. Zealand and Boehringer Ingelheim have developed novel differentiated
long-acting amylin analogues using a unique peptide approach, and Boehringer
Ingelheim plans to advance a lead molecule into clinical testing this year.
Adam Steensberg, Senior Vice President, Chief Medical and Development Officer of
Zealand, comments: "Zealand has two collaborations with Boehringer Ingelheim and
is excited to report progress on the amlyin program. Our amylin analogue, which
has differentiation potential due to its long-acting profile, has shown
significant metabolic benefits in preclinical obesity and diabetes models. We
look forward to the initiation of clinical development of a lead molecule in
2017 to further explore its potential. We are impressed with the thoroughness
and dedication of Boehringer Ingelheim - not only in relation to this long-
acting amylin analogue, but also in relation to our partnership on the long-
acting glucagon/GLP-1 analogue. These are important projects for Zealand, with
significant milestone payments and royalties potentially contributing to growing
revenue in the future."
Under the terms of the two agreements, Boehringer Ingelheim funds all research,
development and commercialization activities. Zealand is eligible to receive
license and milestone payments as follows:
Glucagon/GLP-1 (2011 agreement)
* Up to EUR 376 million, of which EUR 365 million is outstanding in milestone
payments, and high single-digit to low double-digit percentages of global
sales.
Amylin (2014 agreement)
* Up to EUR 295 million, of which EUR 287 million is outstanding in milestone
payments, and low single-digit to low double-digit percentages of global
sales.
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj(at)zealandpharma.com
Mats Blom, Senior Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl(at)zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery, design and development of innovative peptide-
based medicines. Zealand has a portfolio of medicines and product candidates
under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and
a pipeline of product candidates focusing on specialty gastrointestinal and
metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi.
Lixisenatide is marketed as Adlyxin(®) in the U.S. and as Lyxumia(®) in the rest
of the world. Lixisenatide has been developed in a combination with basal
insulin glargine (Lantus(®)) and is marketed as Soliqua(TM) 100/33 in the U.S.
and has been approved as Suliqua(TM) in Europe.
Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207, single-dose
rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide*
(ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-
dose version) intended for use in a dual-hormone artificial pancreas system for
improved hypoglycemia control and diabetes management (Phase 2) and other
earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information
about the Company's business and activities, please visit www.zealandpharma.com
or follow Zealand on Twitter (at)ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names
(pINN).
--------------------------------------------------------------------------------
[i] WHO
3-17_0511 Amylin is biological target in BI agreement:
http://hugin.info/136974/R/2103791/798155.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2017 - 08:57 Uhr
Sprache: Deutsch
News-ID 541793
Anzahl Zeichen: 6093
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 128 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim"
steht unter der journalistisch-redaktionellen Verantwortung von
Zealand Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
